Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESOPEC: FLOT vs CROSS in Esophageal Adenocarcinoma
NCT02509286Phase 3Active, not recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jan 2016
- Primary completion
- May 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, oxaliplatin, folinic acid, fluorouracil in esophageal adenocarcinoma (EAC), sponsored by Universitätsklinikum Schleswig-Holstein. Started Jan 2016; status: active, not recruiting.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracil
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02509286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509286.